TScan Therapeutics Appoints Brian M. Silver, J.D., to Its Board of Directors
Published: Jan 07, 2021 WALTHAM, Mass.--(BUSINESS WIRE)-- TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors. Mr. Silver is Chief Financial Officer and Head of Corporate Development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company. Prior to joining Freeline in 2018, Mr. Silver was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading i...